Your browser doesn't support javascript.
loading
Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia.
Li, Yizhen; Yang, Wentao; Devidas, Meenakshi; Winter, Stuart S; Kesserwan, Chimene; Yang, Wenjian; Dunsmore, Kimberly P; Smith, Colton; Qian, Maoxiang; Zhao, Xujie; Zhang, Ranran; Gastier-Foster, Julie M; Raetz, Elizabeth A; Carroll, William L; Li, Chunliang; Liu, Paul P; Rabin, Karen R; Sanda, Takaomi; Mullighan, Charles G; Nichols, Kim E; Evans, William E; Pui, Ching-Hon; Hunger, Stephen P; Teachey, David T; Relling, Mary V; Loh, Mignon L; Yang, Jun J.
Afiliação
  • Li Y; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Yang W; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Devidas M; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Winter SS; Children's Minnesota Research Institute, Children's Minnesota, Minneapolis, United States of America.
  • Kesserwan C; Center for Cancer Research, Genetics Branch, National Cancer Institute, Bethesda, United States of America.
  • Yang W; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Dunsmore KP; Children's Hematology and Oncology, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, United States of America.
  • Smith C; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Qian M; Department of Hematology and Oncology, Fudan University, Shanghai, China.
  • Zhao X; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Zhang R; Department of Pharmaceutical Sciences, St Jude Childern's Research Hospital, Memphis, United States of America.
  • Gastier-Foster JM; Baylor College of Medicine and Texas Children's Hospital, Houston, United States of America.
  • Raetz EA; Division of Pediatric Hematology and Oncology, New York University Langone Health, New York City, United States of America.
  • Carroll WL; Division of Pediatric Hematology and Oncology, New York University Langone Health, New York City, United States of America.
  • Li C; Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Liu PP; Oncogenesis and Development Section, National Human Genome Research Institute, NIH, Bethesda, United States of America.
  • Rabin KR; Baylor College of Medicine, Texas Children's Cancer and Hematology Centers, Houston, United States of America.
  • Sanda T; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Nichols KE; Department of Oncology, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Evans WE; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Pui CH; Department of Oncology, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Hunger SP; Department of Pediatrics and Center for Childhood Cancer Research, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, United States of America.
  • Teachey DT; Department of Pediatrics, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, United States of America.
  • Relling MV; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
  • Loh ML; Department of Pediatrics, University of California, San Francisco, San Francisco, United States of America.
  • Yang JJ; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States of America.
J Clin Invest ; 2021 Jun 24.
Article em En | MEDLINE | ID: mdl-34166225
ABSTRACT
Genetic alterations in the RUNX1 gene are associated with benign and malignant blood disorders, particularly of megakaryocyte and myeloid lineages. The role of RUNX1 in acute lymphoblastic leukemia (ALL) is less clear, particularly how germline genetic variation influences the predisposition to this type of leukemia. Sequencing 4,836 children with B-ALL and 1,354 cases of T-ALL, we identified 31 and 18 germline RUNX1 variants, respectively. RUNX1 variants in B-ALL consistently showed minimal damaging effects. By contrast, 6 T-ALL-related variants result in drastic loss of RUNX1 activity as a transcription activator in vitro. Ectopic expression of dominant-negative RUNX1 variants in human CD34+ cells repressed differentiation into erythroid, megakaryocytes, and T cells, while promoting myeloid cell development. Chromatin immunoprecipitation sequencing of T-ALL models showed distinctive patterns of RUNX1 binding by variant proteins. Further whole genome sequencing identified JAK3 mutation as the most frequent somatic genomic abnormality in T-ALL with germline RUNX1 variants. Co-introduction of RUNX1 variant and JAK3 mutation in hematopoietic stem and progenitor cells in mice gave rise to T-ALL with early T-cell precursor phenotype. Taken together, these results indicated that RUNX1 is an important predisposition gene for T-ALL and pointed to novel biology of RUNX1-mediated leukemogenesis in the lymphoid lineages.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article